For Consumers

FDA Office of Women's Health Update Archive

 The words Women's Health Alert

 

The Office of Women's Health e-Update highlights women's health initiatives, meetings, and regulatory safety information from the U.S. Food and Drug Administration (FDA). The e-Update is disseminated via email to the public.

Current Issue: February 2017

Message from the Director

 
Through our research and outreach, OWH has been a leader in helping to improve the prevention, diagnosis, and treatment of heart disease and related conditions in women. Our national outreach program provides free heart health education tools for health professionals and community leaders to use to teach women about reducing their risk and making informed decisions about their heart health.
 
For over 20 years, OWH has also supported research to better understand cardiovascular diseases in women and to improve the participation of diverse women in cardiovascular trials. The results of our completed research have contributed to FDA guidance for industry and workshops to foster dialogue and collaboration with public and private partners in the U.S. and internationally. As we build on lessons learned, we are funding studies with the Critical Path Initiative to improve the prediction and prevention of drug-induced heart arrhythmias in women. This research can help potentially improve drug development and safety for both women and men.
 
During American Heart Month, visit our heart research pages and use the educational resources in this update to help improve heart health outcomes for women. I also encourage you to learn about our 2017 research grants which will help to protect and promote the health of women and support product safety.
 
Marsha Henderson - Assistant Commissioner for Women’s Health
 
****************************************
 

Women’s Health Highlights

2017 OWH Research Grants
Research remains an important tool to support FDA’s assessment of the safety and efficacy of medications and other products. Each year, OWH participates in the Office of Chief Scientists Research Grants Harmonization process to identify women’s research projects for funding. This year, OWH selected 7 new research projects for funding based on OWH’s Women’s Health Research Roadmap. The new research strategy and funding structure enable OWH to better support larger studies and cross-center collaborative projects. The outcomes of the research projects will help FDA develop innovative approaches to identify and evaluate the impact of sex differences in the safety and efficacy of medical products used by women.
 
View the 2017 list of OWH-funded research
 
****************************************
New Resources for American Heart Month
OWH offers resources to help women make informed decisions about their heart health. Our new Heart Health toolkit features sample messages you can use on Twitter, Facebook, newsletters and blogs. Share these resources to encourage women in your community to protect their hearts.
 
***************************************
Updated Heart Disease Tools for Researchers
Since 1994, OWH has supported 69 studies that have contributed to the understanding of cardiovascular diseases in women and the development of FDA guidance. Our Research on Heart Disease in Women webpage has been updated to include more research summaries and an overview of the three phases of OWH-funded research on the effects of drugs on women’s heart health.
 
***************************************

Extras

FDA confirms elevated levels of belladonna in certain homeopathic teething products
FDA announced that its laboratory analysis found inconsistent amounts of belladonna, a toxic substance, in certain homeopathic teething tablets, sometimes far exceeding the amount claimed on the label. The agency is warning consumers that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products.
 
Read the press release
 
****************************************

Meetings

 
Joint Devices Advisory Committee Meeting: Ophthalmic and Risk Communication
March 17, 2017, 7:30 am to 4:00 pm
Hilton Washington, DC North/Gaithersburg, Gaithersburg, MD
 __________________________________________________________________ 
 

 Past OWH e-Update Issues

 

Contact FDA

301-796-9440
Fax:301-847-8604
Food and Drug Administration Office of Women's Health

10903 New Hampshire Avenue

WO32-2333

Silver Spring, MD 20993

Page Last Updated: 02/08/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English